Tilray Inc
Change company Symbol lookup
Select an option...
TLRY Tilray Inc
GTX Garrett Motion Inc
ADOC Edoc Acquisition Corp
GM General Motors Co
PKKFF Tenet Fintech Group Inc
NETLF NetLink NBN Trust
VMI Valmont Industries Inc
FF FutureFuel Corp
GLPI Gaming and Leisure Properties Inc
EQNR Equinor ASA
Go

Health Care : Pharmaceuticals | Small Cap Growth
Based in Canada
Company profile

Tilray, Inc. is a global cannabis-lifestyle consumer packaged goods company. The Company operates through five segments cannabis business, distribution business, beverage alcohol business and wellness business. The cannabis business segment is engaged in the cultivation, production, distribution and sale of both medical and adult-use cannabis products. The distribution business segment is engaged in the purchase and resale of pharmaceutical and wellness products to customers. The beverage alcohol business segment is focused on the production, distribution and sale of beverage alcohol products. The wellness business segment offers production, marketing and distribution of hemp-based food and other wellness products. The Company operates in Canada, the United States, Europe, Australia and Latin America.

Closing Price
$8.95
Day's Change
-0.59 (-6.18%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.55
Day's Low
8.69
Volume
(Above Average)
Volume:
26,001,700

10-day average volume:
23,198,905
26,001,700

Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company

6:44 pm ET October 6, 2021 (BusinessWire) Print

Entwistle & Cappucci LLP ("Entwistle & Cappucci") today announced that its ongoing investigation has led to the filing of a class action complaint against Bristol-Myers Squibb Company ("Bristol Myers") and several of its senior executives. The case was filed in the United States District Court for the Southern District of New York, Case No. 1:21-cv-8255.

The action was brought on behalf of all former Celgene Corporation ("Celgene") (NASDAQ: CELG) shareholders that received Contingent Value Rights ("CVRs") in exchange for their Celgene shares pursuant to Bristol Myers' $74 billion acquisition of Celgene on November 20, 2019, and who were damaged thereby (the "Class").

The action arises from Bristol Myers' alleged subversion of the FDA approval process for the purpose of avoiding a $6.4 billion payment to CVR holders. By Bristol Myers' own design, the CVR payout required approval of three blockbuster therapies, including the cancer therapy Liso-cel, by specified dates ("Milestones"). From the outset of the Merger, Bristol Myers allegedly knew it would not take diligent efforts to obtain FDA approval for Liso-cel by the Milestone date of December 31, 2020. Accordingly, the statements in the Joint Proxy concerning the efforts Bristol Myers would make to meet the Milestones, the likelihood that the Milestones would be met and the purported value of the CVRs were materially false and misleading when made.

The complaint asserts claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder. A copy of the complaint may be found on Entwistle & Cappucci's website.

If you wish to serve as a lead plaintiff in this matter, you must file a motion with the Court no later than December 6, 2021. Any member of the proposed Class may move the Court to serve as a lead plaintiff through counsel of their choice, or they may choose to do nothing and remain a member of the Class.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact: Robert N. Cappucci, Esq. of Entwistle & Cappucci at (212) 894-7200 or via e-mail at rcappucci@entwistle-law.com.

About Entwistle & Cappucci

Entwistle & Cappucci is a national law firm providing exceptional legal representation to clients in the most complex and challenging legal matters. Our practice encompasses all areas of litigation, corporate transactions, bankruptcy, insurance, corporate investigations and white-collar defense. Our clients include public and private corporations, major hedge funds, public pension funds, governmental entities, leading institutional investors, domestic and foreign financial services companies, emerging business enterprises and individual entrepreneurs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006006036/en/

SOURCE: Entwistle & Cappucci

Entwistle & Cappucci LLP
www.entwistle-law.com 
Robert N. Cappucci, Esq.
(rcappucci@entwistle-law.com)
Telephone: (212) 894-7200
comtex tracking

COMTEX_394692891/1006/2021-10-06T18:44:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.